Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors

被引：69

作者：

Abdou, Yara ^{[1
]}

Goudarzi, Atta ^{[2
]}

Yu, Jia Xin ^{[3
]}

Upadhaya, Samik ^{[4
]}

Vincent, Benjamin ^{[1
]}

Carey, Lisa A. ^{[1
]}

机构：

[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA

[2] Univ Buffalo, Dept Med, Buffalo, NY 14203 USA

[3] Parker Inst Canc Immunotherapy, San Francisco, CA 94129 USA

[4] Canc Res Inst, New York, NY 10006 USA

来源：

NPJ BREAST CANCER | 2022年 / 8卷 / 01期

关键词：

TUMOR-INFILTRATING LYMPHOCYTES; RANDOMIZED PHASE-II; METASTATIC BREAST; NEOADJUVANT CHEMOTHERAPY; TALIMOGENE LAHERPAREPVEC; T-CELLS; PEPTIDE VACCINE; DENDRITIC CELLS; DOUBLE-BLIND; TRIAL;

D O I：

10.1038/s41523-022-00486-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The development of immunotherapy agents has revolutionized the field of oncology. The only FDA-approved immunotherapeutic approach in breast cancer consists of immune checkpoint inhibitors, yet several novel immune-modulatory strategies are being actively studied and appear promising. Innovative immunotherapeutic strategies are urgently needed in triple negative breast cancer (NBC), a subtype of breast cancer known for its poor prognosis and its resistance to conventional treatments. TNBC is more primed to respond to immunotherapy given the presence of more tumor infiltrating lymphocytes, higher PD-L1 expression, and higher tumor mutation burden relative to the other breast cancer subtypes, and therefore, immuno-oncology represents a key area of promise for TNBC research. The aim of this review is to highlight current data and ongoing efforts to establish the safety and efficacy of immunotherapeutic approaches beyond checkpoint inhibitors in TNBC.

引用

页数：10

共 116 条

[31] PROGNOSTIC VALUE OF CEA AND FERRITIN ASSAY IN BREAST-CANCER - A MULTIVARIATE-ANALYSIS [J].

GAGLIA, P ;

CALDAROLA, B ;

BUSSONE, R ;

POTENTE, F ;

LAURO, D ;

JAYME, A ;

CALDAROLA, L .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (07) :1151-1155

[32] Driving T-cell immunotherapy to solid tumors [J].

Garber, Ken .

NATURE BIOTECHNOLOGY, 2018, 36 (03) :215-219

[33] Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting [J].

Garcia-Teijido, Paula ;

Luque Cabal, Maria ;

Pelaez Fernandez, Ignacio ;

Fernandez Perez, Yolanda .

CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2016, 10 :31-39

[34] If we build it they will come: targeting the immune response to breast cancer [J].

Gatti-Mays, Margaret E. ;

Balko, Justin M. ;

Gameiro, Sofia R. ;

Bear, Harry D. ;

Prabhakaran, Sangeetha ;

Fukui, Jami ;

Disis, Mary L. ;

Nanda, Rita ;

Gulley, James L. ;

Kalinsky, Kevin ;

Sater, Houssein Abdul ;

Sparane, Joseph A. ;

Cescon, David ;

Page, David B. ;

McArthur, Heather ;

Adams, Sylvia ;

Mittendorf, Elizabeth A. .

NPJ BREAST CANCER, 2019, 5 (1)

[35] Immunization of metastatic breast cancer patients with a fully synthetic globe H conjugate: A phase I trial [J].

Gilewski, T ;

Ragupathi, G ;

Bhuta, S ;

Williams, LJ ;

Musselli, C ;

Zhang, XF ;

Bencsath, KP ;

Panageas, KS ;

Chin, J ;

Hudis, CA ;

Norton, L ;

Houghton, AN ;

Livingston, PO ;

Danishefsky, SJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (06) :3270-3275

[36] Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma [J].

Gulley, James L. ;

Arlen, Philip M. ;

Tsang, Kwong-Yok ;

Yokokawa, Junko ;

Palena, Claudia ;

Poole, Diane J. ;

Remondo, Cinzia ;

Cereda, Vittore ;

Jones, Jacquin L. ;

Pazdur, Mary P. ;

Higgins, Jack P. ;

Hodge, James W. ;

Steinberg, Seth M. ;

Kotz, Herbert ;

Dahut, William L. ;

Schlom, Jeffrey .

CLINICAL CANCER RESEARCH, 2008, 14 (10) :3060-3069

[37] Preliminary safety data of intrahepatic talimogene laherparepvec and intravenous atezolizumab in patients with triple negative breast cancer [J].

Hecht, Joel Randolph ;

Chan, Arlene ;

Baurain, Jean-Francois ;

Martin, Miguel ;

Longo-Munoz, Federico ;

Kalinsky, Kevin ;

Raman, Steven ;

Liu, Chunxu ;

Cha, Edward ;

Chan, Emily .

CANCER RESEARCH, 2020, 80 (04)

[38] Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer A Randomized Clinical Trial [J].

Heery, Christopher R. ;

Ibrahim, Nuhad K. ;

Arlen, Philip M. ;

Mohebtash, Mahsa ;

Murray, James L. ;

Koenig, Kimberly ;

Madan, Ravi A. ;

McMahon, Sheri ;

Marte, Jennifer L. ;

Steinberg, Seth M. ;

Donahue, Renee N. ;

Grenga, Italia ;

Jochems, Caroline ;

Farsaci, Benedetto ;

Folio, Les R. ;

Schlom, Jeffrey ;

Gulley, James L. .

JAMA ONCOLOGY, 2015, 1 (08) :1087-1095

[39] Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury [J].

Heery, Christopher R. ;

Singh, B. Harpreet ;

Rauckhorst, Myrna ;

Marte, Jennifer L. ;

Donahue, Renee N. ;

Grenga, Italia ;

Rodell, Timothy C. ;

Dahut, William ;

Arlen, Philip M. ;

Madan, Ravi A. ;

Schlom, Jeffrey ;

Gulley, James L. .

CANCER IMMUNOLOGY RESEARCH, 2015, 3 (11) :1248-1256

[40] A randomized phase II study of nab-paclitaxel plus durvalumab plus neoantigen vaccine versus nab-paclitaxel plus durvalumab in metastatic triple-negative breast cancer (mTNBC). [J].

Hernandez-Aya, Leonel Fernando ;

Gao, Feng ;

Goedegebuure, Peter S. ;

Ma, Cynthia X. ;

Ademuyiwa, Foluso Olabisi ;

Park, Haeseong ;

Peterson, Lindsay Leuthen ;

Bagegni, Nusayba Ali ;

Bose, Ron ;

Gillanders, William E. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 6 7 8 9 10 →